Leadership & Pay ·
Appoints Dean Zikria Interim CEO, Unveils 30-Day Agenda to Advance Entolimod and Evaluate Velocity Bioworks
TIVCValion Bio, Inc.
Valion Bio appointed Dean Zikria as interim chief executive officer. Zikria outlined a strategic agenda prioritizing the advancement of lead asset Entolimod for Acute Radiation Syndrome, commercial expansion of CDMO subsidiary Velocity Bioworks, and evaluation of strategic transactions such as partnerships or sales to unlock value. The company has not committed to any specific transaction regarding Velocity. Valion Bio is a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways.